Video

Dr. Oh on Sequencing New Treatments for Prostate Cancer

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, explains that in the past few years more than six new therapies for treating castration-resistant prostate cancer (CRPC) have been approved and now the challenge facing many physicians is how to optimally sequence these therapies.

The guiding principles for sequencing any therapeutic is to begin with the treatment that is the most effective with the least toxicities. Following this approach, treatments can be further sequenced using the mechanism of action (MOA) as a guide. Oh notes, that each of the newly approved therapies for CRPC seem to represent a unique MOA, including cytotoxic agents, immunotherapies, androgen therapies, radiopharmaceuticals, and others.

As an example, Oh notes that, since these therapies have multiple MOAs, if a patient does not do well on hormonal therapy another option is available that uses a different approach, such as a cytotoxic. Additionally, he adds that immunotherapies should likely be administered in the frontline, when the immune system is at its strongest.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine